Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sekar Kathiresan

Showing results (1-10 of 362) with videos related to

Pageof 37
Sort By:
The New England Journal of Medicine|December 25, 2009
Lp(a) lipoprotein redux--from curious molecule to causal risk factorSekar Kathiresan
Journal of the American College of Cardiology|October 23, 2012
Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trialsSekar Kathiresan
Nature|August 29, 2017
Heart disease: Putative medicines that mimic mutationsSekar Kathiresan
Journal of the American College of Cardiology|April 18, 2015
Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETPSekar Kathiresan
American Journal of Human Genetics|March 9, 2019
2018 Curt Stern Award AddressSekar Kathiresan
The New England Journal of Medicine|May 24, 2008
A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarctionSekar Kathiresan,
Cell|March 20, 2012
Genetics of human cardiovascular diseaseSekar Kathiresan, Deepak Srivastava
Cell|March 23, 2019
Genetics of Common, Complex Coronary Artery DiseaseKiran Musunuru, Sekar Kathiresan
Annual Review of Genomics and Human Genetics|July 2, 2010
Genetics of coronary artery diseaseKiran Musunuru, Sekar Kathiresan
Nature Reviews. Endocrinology|July 15, 2017
Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?Kiran Musunuru, Sekar Kathiresan
Pageof 37

Showing results (1-10 of 362) with videos related to

Sort By:
Pageof 37
The New England Journal of Medicine|December 25, 2009
Lp(a) lipoprotein redux--from curious molecule to causal risk factorSekar Kathiresan
Journal of the American College of Cardiology|October 23, 2012
Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trialsSekar Kathiresan
Nature|August 29, 2017
Heart disease: Putative medicines that mimic mutationsSekar Kathiresan
Journal of the American College of Cardiology|April 18, 2015
Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETPSekar Kathiresan
American Journal of Human Genetics|March 9, 2019
2018 Curt Stern Award AddressSekar Kathiresan
The New England Journal of Medicine|May 24, 2008
A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarctionSekar Kathiresan,
Cell|March 20, 2012
Genetics of human cardiovascular diseaseSekar Kathiresan, Deepak Srivastava
Cell|March 23, 2019
Genetics of Common, Complex Coronary Artery DiseaseKiran Musunuru, Sekar Kathiresan
Annual Review of Genomics and Human Genetics|July 2, 2010
Genetics of coronary artery diseaseKiran Musunuru, Sekar Kathiresan
Nature Reviews. Endocrinology|July 15, 2017
Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?Kiran Musunuru, Sekar Kathiresan
Pageof 37